PROCEPT BioRobotics/$PRCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
- Ticker
- $PRCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 888
- Headquarters
- San Jose, United States
- Website
- www.procept-biorobotics.com
PRCT Metrics
BasicAdvanced
$1.1B
-
-$1.95
0.90
-
Price and volume
Market cap
$1.1B
Beta
0.9
52-week high
$38.11
52-week low
$16.67
Average daily volume
1.2M
Financial strength
Current ratio
6.547
Quick ratio
5.226
Long term debt to equity
0.221
Total debt to equity
0.228
Interest coverage (TTM)
-33.73%
Profitability
EBITDA (TTM)
-107.432
Gross margin (TTM)
63.36%
Net profit margin (TTM)
-32.54%
Operating margin (TTM)
-33.86%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-30.24%
Valuation
Price to revenue (TTM)
3.207
Price to book
3.23
Price to tangible book (TTM)
3.23
Price to free cash flow (TTM)
-12.739
Free cash flow yield (TTM)
-7.85%
Free cash flow per share (TTM)
-1.507
Growth
Revenue change (TTM)
22.69%
Earnings per share change (TTM)
25.13%
3-year revenue growth (CAGR)
49.17%
3-year earnings per share growth (CAGR)
-5.80%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Analyst projections of the future price of PROCEPT BioRobotics stock.
Bulls say / Bears say
Revenue rose 19% year on year in Q2, while US procedures grew 21%, and management maintained its 2026 revenue growth outlook of 27% to 33%. That points to continuing adoption despite a slower quarter than management expected. (PROCEPT BioRobotics)
New HYDROS accounts are generating more procedures per system than legacy AquaBeam accounts, and PROCEPT placed 65 HYDROS systems in the US in Q2. If the replacement programme lifts use at older sites, it could support procedure growth over time. (PROCEPT BioRobotics)
The American Urological Association strengthened its recommendation for Aquablation in its updated BPH guidelines. That added clinical backing may help hospitals and clinicians adopt the treatment more widely. (PROCEPT BioRobotics)
Q2 procedure growth was softer than management expected, mainly because of weaker use at legacy AquaBeam sites, and the company lowered its full-year US procedure outlook. Continued weakness there could constrain growth even as new HYDROS systems are placed. (The Motley Fool)
The Q2 net loss widened to $26.9 million from $19.6 million a year earlier, while operating expenses rose 21%. The company also used $57.4 million in operating cash in the first half, leaving profitability and funding needs as material risks. (SEC)
A proposed 30% increase in Medicare reimbursement for prostate artery embolisation at ambulatory surgery centres could make that alternative more attractive financially to providers. If the proposal leads to a shift in physician preference, it could weigh on Aquablation use. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRCT News
AllArticlesVideos
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Take Immediate Action in the Securities Class Action Before September 22, 2026
Newsfile Corp1 month ago
Kaplan Fox Alerts PROCEPT BioRobotics Corporation (PRCT) Investors With Losses to a Securities Class Action - Act Before the September 22, 2026 Deadline
Newsfile Corp1 month ago
PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire1 month ago
Funds containing PRCT
AllUSDEURGBP
Fund name | Fund size | $PRCT weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.